D-0501-2017 Class II Terminated
FDA drug recall D-0501-2017 was initiated by G & W Laboratories, Inc. on Feb 7, 2017 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Out of specification (OOS) for total impurity and out of trend for known impurity results encountered during stability testing. The recall status is terminated (terminated Jun 18, 2018). Affected quantity: 3456 boxes.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 8, 2017
- Initiation Date
- Feb 7, 2017
- Termination Date
- Jun 18, 2018
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 3456 boxes
Product description
Indocin (Indomethacin) suppositories, USP, 50 mg, laminate strips packed in boxes of 30, Rx only, Manufactured by: G&W Laboratories Inc. South Plainfield, NJ 07080, Distributed by Iroko Pharmaceuticals, LLC Philadelphia, PA 19112, NDC 42211-0102-43
Reason for recall
Failed Impurities/Degradation Specifications: Out of specification (OOS) for total impurity and out of trend for known impurity results encountered during stability testing.
Distribution pattern
Within United States
Code information
Lot #: 017600011, Exp. Jan 2018, 0176000014, Exp. Aug 2018, 017600015, Exp. Sep 2018
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0501-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026